For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic ...
Most people with atopic dermatitis (a type of eczema) are able to control their symptoms by using topical treatments that are applied to the skin. But for some people with severe atopic dermatitis, ...
Up until a few years ago, Heather Sullivan’s 14-year-old son, Sawyer, had struggled with eczema his entire life. When he was just a baby, most of his body would be covered in intensely itchy rashes ...
Current treatments for chronic hand eczema (CHE) generally fall into two buckets: Either they battle inflammation but lead to unwanted side effects with long-term use or they soothe external symptoms ...
Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.
SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a blockbuster drug Sanofi codeveloped with Regeneron PharmaceuticalsREGN.
A Nektar Therapeutics drug has met the skin clearance goals of a closely watched mid-stage clinical trial in atopic dermatitis. While these preliminary results bring validation to the therapy’s novel ...
Sanofi reported Thursday gains in first-quarter sales and operating income, boosted by strong sales of vaccines and the anti-inflammatory drug Dupixent. Sanofi is the French parent company of Sanofi ...
Sanofi (NASDAQ:SNY) and partner Regeneron Pharmaceuticals (NASDAQ:REGN) announced Friday the receipt of priority review for their supplemental biologics license application (sBLA) for Dupixent ...
The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood Children treated with Dupixent and topical corticosteroids (TCS) ...
(Reuters) -Sanofi and partner Regeneron Pharmaceuticals have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback